Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cyproheptadine
Drug ID BADD_D00552
Description Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors.[L32474] It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation[L32519] and its off-label use in the treatment of serotonin syndrome.[A231274]
Indications and Usage In the US, prescription cyproheptadine is indicated for the treatment of various allergic symptomatologies - including dermatographia, rhinitis, conjunctivitis, and urticaria - as well as adjunctive therapy in the management of anaphylaxis following treatment with epinephrine.[L32474] In Canada, cyproheptadine is available over-the-counter and is indicated for the treatment of pruritus and for appetite stimulation.[L32519] In Australia, cyproheptadine is additionally indicated for the treatment vascular headaches.[L32479] Cyproheptadine is also used off-label for the treatment of serotonin syndrome.[A231274]
Marketing Status approved
ATC Code R06AX02
DrugBank ID DB00434
KEGG ID D07765
MeSH ID D003533
PubChem ID 2913
TTD Drug ID D00TLN
NDC Product Code Not Available
UNII 2YHB6175DO
Synonyms Cyproheptadine | Dihexazin | Peritol | Viternum | Antergan | Periactin
Chemical Information
Molecular Formula C21H21N
CAS Registry Number 129-03-3
SMILES CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Irritability08.01.03.011; 19.04.02.013--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Labyrinthitis11.01.05.002; 04.04.03.001--Not Available
Leukopenia01.02.02.001--Not Available
Loss of consciousness17.02.04.004--Not Available
Menstruation irregular05.05.01.008; 21.01.01.005--
Nasal congestion22.04.04.001--
Nasal dryness22.04.03.002--Not Available
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Neuritis17.09.03.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Oedema08.01.07.006; 14.05.06.010--Not Available
Palpitations02.11.04.012--
Paraesthesia23.03.03.094; 17.02.06.005--
Photosensitivity reaction23.03.09.003--
Pollakiuria20.02.02.007--
Rash23.03.13.001--Not Available
Restlessness17.02.05.021; 19.11.02.002--
Sedation17.02.04.005--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Syncope24.06.02.012; 17.02.04.008; 02.11.04.015--
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene